EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MicroRNA-142-3p Overcomes Drug Resistance in Hepatocellular Carcinoma by Targeting YES1 and TWF1

Khadijeh Mahboobnia iD, Tasnuva D Kabir iD, Rui Hou iD, Peiwen Liu, Alistair Forrest, Dianne J Beveridge iD, Kirsty L Richardson, Lisa M Stuart, George C Yeoh, Peter J Leedman iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26094161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Khadijeh Mahboobnia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Harry Perkins Institute of Medical Research, QEII Medical Centre, 6 Verdun St, Nedlands, Perth, WA 6009, Australia. Hauptthemen laut MEDLINE: MicroRNAs, Carcinoma, Hepatocellular, Liver Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHMRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance to tyrosine kinase inhibitors (TKIs, e.g., sorafenib and lenvatinib) presents a significant hurdle for hepatocellular carcinoma (HCC) treatment, underscoring the need to decipher the underlying mechanisms for improved therapeutic strategies. MicroRNAs (miRNAs) have emerged as critical modulators in HCC progression and TKI resistance. In this study, we report a positive correlation between the expression levels of a tumor suppressor miRNA, miR-142-3p, and increased sensitivity to sorafenib and lenvatinib, supported by clinical data from the BIOSTORM HCC cohort. Overexpression of miR-142-3p in TKI-resistant HCC cells significantly inhibited proliferation and colony formation, induced apoptosis, increased cell cycle arrest at the G2 phase, and reduced migration and invasion by reversing epithelial–mesenchymal transition. Notably, combining miR-142-3p with lenvatinib synergistically inhibited growth in both inherent and acquired TKI-resistant HCC cells by modulating critical signaling pathways, including STAT3, PI3K/AKT, MAPK, YAP1, and by impeding autophagic influx. RNA-sequencing of a TKI-resistant HCC cell line ± miR-142-3p overexpression identified YES1 and TWF1 as direct downstream target genes of miR-142-3p, both of which are key genes associated with drug resistance in HCC. Small interfering RNA (siRNA)-mediated knockdown of these genes mirrored the antitumor effects of miR-142-3p and enhanced TKI sensitivity, with YES1 knockdown decreasing YAP1 phosphorylation, and TWF1 knockdown inhibiting autophagy. Collectively, these findings indicate that restoring miR-142-3p expression or targeting its downstream effectors YES1 and TWF1 offers a promising strategy to overcome drug resistance and improve therapeutic outcome in HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsCarcinoma, HepatocellularLiver NeoplasmsDrug Resistance, NeoplasmProto-Oncogene Proteins c-yesHumansCell Line, TumorGene Expression Regulation, NeoplasticCell ProliferationSorafenibPhenylurea CompoundsApoptosisQuinolinesEpithelial-Mesenchymal TransitionCell MovementProtein Kinase InhibitorsSignal Transduction

Stichwörter der Autor:innen

TWF1YES1drug resistancehepatocellular carcinomamiR-142-3ptyrosine kinase inhibitors

Substanzen

MicroRNAsMIRN142 microRNA, humanProto-Oncogene Proteins c-yesYES1 protein, humanSorafenibPhenylurea CompoundsQuinolineslenvatinibProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Harry Perkins Institute of Medical Research, QEII Medical Centre, 6 Verdun St, Nedlands, Perth, WA 6009, Australia.
  • Centre for Medical Research, The University of Western Australia, Perth, WA 6009, Australia.
  • School of Molecular Sciences, The University of Western Australia, Perth, WA 6009, Australia.

ORCID-Profile: Khadijeh Mahboobnia, Tasnuva D Kabir, Rui Hou, Dianne J Beveridge, Peter J Leedman

Förderung

  • NHMRC

Zitieren

APA

Mahboobnia, K., Kabir, T. D., Hou, R., Liu, P., Forrest, A., Beveridge, D. J., Richardson, K. L., Stuart, L. M., Yeoh, G. C., & Leedman, P. J. (2025). MicroRNA-142-3p Overcomes Drug Resistance in Hepatocellular Carcinoma by Targeting YES1 and TWF1. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26094161

Vancouver

Mahboobnia K, Kabir TD, Hou R, Liu P, Forrest A, Beveridge DJ, et al. MicroRNA-142-3p Overcomes Drug Resistance in Hepatocellular Carcinoma by Targeting YES1 and TWF1. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26094161

BibTeX
@article{Mahboobnia2025,
  author = {Mahboobnia, Khadijeh and Kabir, Tasnuva D and Hou, Rui and Liu, Peiwen and Forrest, Alistair and Beveridge, Dianne J and Richardson, Kirsty L and Stuart, Lisa M and Yeoh, George C and Leedman, Peter J},
  title = {MicroRNA-142-3p Overcomes Drug Resistance in Hepatocellular Carcinoma by Targeting YES1 and TWF1},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26094161}
}
Kostenlos starten →